Although the overall predominance of the type-2 immune response in AD has been described using Omics techniques59 and clinical trials demonstrated that a therapy targeting IL-17 only is not successful32, this study describes the pro-inflammatory potential of IL-17 in skin inflammation after allergen-challenge. Here, IL17A is linked to Alzheimer disease.